MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)

梅哈里医学院(MMC)、田纳西州立大学(TSU)和范德比尔特-英格拉姆癌症中心(VICC)的癌症研究人员之间建立了牢固的联系，导致了这一正式的癌症伙伴关系。我们的伙伴关系致力于增强我们三个机构的优势，消除我们三个机构的弱点，朝着我们在美国消除癌症差异的共同目标迈进。U54奖是这种合作的基石，它更有力地推动了我们的合作研究，使我们之间的关系建立在互惠和更强大的互惠互利的基础上。这项相互竞争的续签申请的总体目标是：(1)增加和稳定MMC和TSU具有竞争力的癌症研究能力；(2)在MMC、TSU和VICC之间建立稳定的、长期的合作关系，包括癌症研究、研究培训、职业发展和癌症推广；以及(3)提高VICC研究、培训、职业发展、癌症教育和癌症推广活动的有效性，专门旨在造福VICC所服务地区的少数族裔人口。这款U54提供的资金将巩固我们的合作。在我们癌症伙伴关系的这一阶段，我们继续致力于为癌症研究积累足够的基础设施，以加强MMC、TSU和VICC之间的互惠。除了资助两个完整的项目和两个涉及所有三个机构的合作者的试验性研究外，资金还将用于招聘TSU和VICC的研究人员，并通过支持提供生物统计学、临床试验应计费用、组织病理学和癌症外展专业知识的核心设施，加强基础、流行病学和临床癌症研究的基础设施。所有活动都涉及MMC、TSU和VICC之间协调、计划周密的互动，并将由一个由每个机构的成员组成的内部咨询委员会和一个由国家认可的外部癌症研究人员和国家癌症研究所的代表组成的项目指导委员会进行监督。一个持续和全面的癌症伙伴关系对三个参与机构以及美国中南部地区都有巨大的好处。该机构的优势互补将有助于癌症伙伴关系建立有效的癌症研究，并在两个为少数群体服务的机构增加培训机会，加强针对少数群体癌症相关差异的社区和人口科学研究，并在NCI资助的综合癌症中心增加对少数群体科学家的培训。

Strong ties have developed between cancer researchers at Meharry Medical College (MMC), Tennessee State University (TSU) and Vanderbilt-lngram Cancer Center (VICC) resulting in this formal Cancer Partnership. Our Partnership is dedicated to enhancing the strengths and eliminating the weaknesses of our three institutions as we move toward our shared goal of eliminating cancer disparities in the US. The U54 award is the bedrock of this collaboration and has moved our collaborative research more forcefully toward a relationship that is based on reciprocity and stronger mutual benefit. The overall objectives of this competing renewal application are: (1) to increase and stabilize the competitive cancer research capability of MMC and TSU; (2) to create stable, long-term collaborative relationships between MMC, TSU and the VICC in cancer research, research training, career development and cancer outreach; and (3) to improve the effectiveness of VICC research, training, career development, cancer education and cancer outreach activities specifically designed to benefit minority populations in the region served by VICC. Funds provided by this U54 will solidify our collaboration. During this phase of our Cancer Partnership, we continue to concentrate on amassing sufficient infrastructure for cancer research that will strengthen reciprocity between MMC, TSU and VICC. In addition to funding two full projects and two pilot studies involving collaborators from all three institutions, funds will be used to recruit investigators to TSU and VICC and to strengthen infrastructure in basic, epidemiologic and clinical cancer research through the support of core facilities providing expertise in biostatistics, clinical trial accruals, histopathology and cancer outreach. All activities involve coordinated, well-planned interactions between MMC, TSU and VICC and will be monitored by an Internal Advisory Committee composed of members from each institution and a Program Steering Committee composed of external, nationally-recognized cancer investigators and representation from the National Cancer Institute. A sustained and comprehensive Cancer Partnership is of immense benefit to the three participating institutions as well as the mid-South region of the US. The institution's complementary strengths will help the Cancer Partnership establish effective cancer research and increase training opportunities at two minority-serving institutions enhance community- and population-based science research targeting minority cancer-related disparities and increase training of minority scientists at an NCI-funded Comprehensive Cancer Center.